What is the address of DOKTER KIM GEYBELS ACUTE GENEESKUNDE?

The registered office of DOKTER KIM GEYBELS ACUTE GENEESKUNDE is located at Eikeldreef 6A, 9830 Sint-Martens-Latem.

Is DOKTER KIM GEYBELS ACUTE GENEESKUNDE still active?

Yes. According to the CBE (17 September 2026) DOKTER KIM GEYBELS ACUTE GENEESKUNDE is active, legal situation “Normale toestand”, started on 21 May 2010.

Is DOKTER KIM GEYBELS ACUTE GENEESKUNDE registered on Peppol?

Yes, DOKTER KIM GEYBELS ACUTE GENEESKUNDE is registered on the Peppol network with ID 0208:0826068430.

What is the enterprise number of DOKTER KIM GEYBELS ACUTE GENEESKUNDE?

The enterprise number of DOKTER KIM GEYBELS ACUTE GENEESKUNDE is BE0826068430.

When was DOKTER KIM GEYBELS ACUTE GENEESKUNDE founded?

DOKTER KIM GEYBELS ACUTE GENEESKUNDE was founded on 21 May 2010.

Who are the directors of DOKTER KIM GEYBELS ACUTE GENEESKUNDE?

According to the 2024 annual accounts, the directors of DOKTER KIM GEYBELS ACUTE GENEESKUNDE are: Kim Geybels.

Is DOKTER KIM GEYBELS ACUTE GENEESKUNDE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 21 May 2010; 4 annual accounts filed, latest fiscal year 2024; 1 directors known from the annual account.

How much profit did DOKTER KIM GEYBELS ACUTE GENEESKUNDE make in 2024?

DOKTER KIM GEYBELS ACUTE GENEESKUNDE posted a profit after taxes of € 78,369 in financial year 2024.

What is the revenue of DOKTER KIM GEYBELS ACUTE GENEESKUNDE?

As a small company, DOKTER KIM GEYBELS ACUTE GENEESKUNDE is not required to publish revenue in its annual accounts. In financial year 2024, its added value was € 113,368.

DOKTER KIM GEYBELS ACUTE GENEESKUNDE (Private Limited)

Dossier DOKTER KIM GEYBELS ACUTE GENEESKUNDE, printed on 17 September 2026 from databakkes.be/en/0826068430/dokter-kim-geybels-acute-geneeskunde. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2024

DOKTER KIM GEYBELS ACUTE GENEESKUNDE from Sint-Martens-Latem, company number BE0826068430, closed financial year 2024 with a result of € 78,369 after tax. For that financial year DOKTER KIM GEYBELS ACUTE GENEESKUNDE recorded a gross margin of € 113,368 and equity of € 244,189. Compared with financial year 2023, the result moved from € 21,799 to € 78,369. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 29, 2025.

What it is worth Growing

€ 244,189

▲ 47% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 78,369

▲ 260% vs 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 7,749

▲ € 7,737 vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2024. Retained profit grew to € 231,789.

People and assets in 2024

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Debts at end 2024

Bank debt

€ 3,814

▲ 3% vs 2023

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 1,315

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 28,870

▲ 134% vs 2023

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Gross margin	€ 41,694 Gross margin 2021: € 41,694 First fiscal year in the series	€ 85,748 Gross margin 2022: € 85,748 ▲ 106% vs 2021 (€ 41,694) Favourable step	€ 32,611 Gross margin 2023: € 32,611 ▼ 62% vs 2022 (€ 85,748) Unfavourable step	€ 113,368 Gross margin 2024: € 113,368 ▲ 248% vs 2023 (€ 32,611) Favourable step	▲ 248%
Profit after taxes	€ 25,985 Profit after taxes 2021: € 25,985 First fiscal year in the series	€ 59,013 Profit after taxes 2022: € 59,013 ▲ 127% vs 2021 (€ 25,985) Favourable step	€ 21,799 Profit after taxes 2023: € 21,799 ▼ 63% vs 2022 (€ 59,013) Unfavourable step	€ 78,369 Profit after taxes 2024: € 78,369 ▲ 260% vs 2023 (€ 21,799) Favourable step	▲ 260%
Equity	€ 85,008 Equity 2021: € 85,008 First fiscal year in the series	€ 144,021 Equity 2022: € 144,021 ▲ 69% vs 2021 (€ 85,008) Favourable step	€ 165,820 Equity 2023: € 165,820 ▲ 15% vs 2022 (€ 144,021) Favourable step	€ 244,189 Equity 2024: € 244,189 ▲ 47% vs 2023 (€ 165,820) Favourable step	▲ 47%
Total debts	€ 75,639 Total debts 2021: € 75,639 First fiscal year in the series	€ 25,773 Total debts 2022: € 25,773 ▼ 66% vs 2021 (€ 75,639) Favourable step	€ 42,500 Total debts 2023: € 42,500 ▲ 65% vs 2022 (€ 25,773) Unfavourable step	€ 37,533 Total debts 2024: € 37,533 ▼ 12% vs 2023 (€ 42,500) Favourable step	▼ 12%
Cash	€ 5,220 Cash 2021: € 5,220 First fiscal year in the series	€ 8,551 Cash 2022: € 8,551 ▲ 64% vs 2021 (€ 5,220) Favourable step	€ 12 Cash 2023: € 12 ▼ € 8,539 vs 2022 (€ 8,551) Unfavourable step	€ 7,749 Cash 2024: € 7,749 ▲ € 7,737 vs 2023 (€ 12) Favourable step	▲ € 7,737
Retained profit	€ 72,608 Retained profit 2021: € 72,608 First fiscal year in the series	€ 131,621 Retained profit 2022: € 131,621 ▲ 81% vs 2021 (€ 72,608) Favourable step	€ 153,420 Retained profit 2023: € 153,420 ▲ 17% vs 2022 (€ 131,621) Favourable step	€ 231,789 Retained profit 2024: € 231,789 ▲ 51% vs 2023 (€ 153,420) Favourable step	▲ 51%
Bank debt	€ 16,237 Bank debt 2021: € 16,237 First fiscal year in the series	€ 10,915 Bank debt 2022: € 10,915 ▼ 33% vs 2021 (€ 16,237) Favourable step	€ 3,714 Bank debt 2023: € 3,714 ▼ 66% vs 2022 (€ 10,915) Favourable step	€ 3,814 Bank debt 2024: € 3,814 ▲ 3% vs 2023 (€ 3,714) Unfavourable step	▲ 3%
Balance sheet total	€ 160,647 Balance sheet total 2021: € 160,647 First fiscal year in the series	€ 169,794 Balance sheet total 2022: € 169,794 ▲ 6% vs 2021 (€ 160,647) Unchanged	€ 208,320 Balance sheet total 2023: € 208,320 ▲ 23% vs 2022 (€ 169,794) Unchanged	€ 281,722 Balance sheet total 2024: € 281,722 ▲ 35% vs 2023 (€ 208,320) Unchanged	▲ 35%

Key figures of DOKTER KIM GEYBELS ACUTE GENEESKUNDE, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to DOKTER KIM GEYBELS ACUTE GENEESKUNDE?

What happened at DOKTER KIM GEYBELS ACUTE GENEESKUNDE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 29, 2025 New annual accounts for financial year 2024: profit of € 78,369 (▲ 260% vs 2023). filed late Source: NBB ↗
May 21, 2010 Start of the company according to the CBE. KBO
May 19, 2010 New establishment in Sint-Martens-Latem. KBO
2010 Kim Geybels became a director. NBB

In short

From € 25,985 profit in 2021 to € 78,369 profit in 2024.

Paid € 93,404 in corporate taxes since 2021.

Best year ever: 2024, with € 78,369 profit.

Original PDFs at the National Bank ↗

A new publication or filing at DOKTER KIM GEYBELS ACUTE GENEESKUNDE? We notify you, reason included.

Follow DOKTER KIM GEYBELS ACUTE GENEESKUNDE

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Kim Geybels

DOKTER KIM GEYBELS ACUTE GENEESKUNDE

Behind DOKTER KIM GEYBELS ACUTE GENEESKUNDE is Kim Geybels.

See the full network in the app

Directors

According to the 2024 annual accounts

Kim Geybels

Director

since 2010

Establishments

Establishment units

Physical locations of this company

Registered office

Eikeldreef 6A

9830 Sint-Martens-Latem

2.189.229.325

Eikeldreef 6 box A

9830 Sint-Martens-Latem

Active since 19 May 2010

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0826.068.430
VAT number: BE 0826.068.430
Registered office: Eikeldreef 6A, 9830 Sint-Martens-Latem
Names & denominations: DOKTER KIM GEYBELS ACUTE GENEESKUNDE
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 21 May 2010
Peppol: Active · Active since 23 Dec 2025

View on CBE Public ↗ Annual accounts (NBB) ↗